Our data confirmed that patients with NSCLC with a higher RANKL: OPG ratio more often developed bone metastases, primarily in the first 450 days after diagnosis of metastatic NSCLC. This evidence concerns the gene TNFRSF11B and non-small cell lung carcinoma.